Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
Takuya ShoGoki SudaKoji OgawaMegumi KimuraAkinori KuboYoshimasa TokuchiTakashi KitagatayaOsamu MaeharaShunsuke OhnishiTaku ShigesawaAkihisa NakamuraRen YamadaMasatsugu OharaNaoki KawagishiMitsuteru NatsuizakaMasato NakaiKenichi MorikawaKen FuruyaMasaru BabaYoshiya YamamotoKazuharu SuzukiTakaaki IzumiTakashi MeguroKatsumi TerashitaJun ItoTakuto MiyagishimaNaoya SakamotoPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
Most patients treated with atezolizumab plus bevacizumab did not meet the IMbrave150 criteria; however, the combination therapy showed good safety and efficacy at the early treatment phase.